All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The PsOPsA Hub is an independent medical education platform. This activity is supported by an educational grant from Lilly. Funders are allowed no direct influence on our content.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Bimekizumab efficacy across GRAPPA domains: Pooled phase III results through 3 years in PsA

By Megan Moore

Share:

Nov 19, 2026

Learning objective: After reading this article, learners will be able to cite a new clinical development in psoriatic arthritis.


A post hoc analysis of pooled data from the randomized, multicenter, double-blind, placebo-controlled, phase III BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) studies and their open-label extension BE VITAL (NCT04009499) evaluated the efficacy of bimekizumab through 3 years across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains in patients with active psoriatic arthritis (PsA) who were biologic disease-modifying antirheumatic drug (bDMARD)-naïve (BE OPTIMAL) or had prior inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi; BE COMPLETE). Results were published in Rheumatology by Deodhar et al. 

Key data: At Year 3, in the overall bimekizumab-treated population (n = 1,112), including patients who switched from placebo to bimekizumab at Week 16, 59.2% and 34.6% of patients had resolution of swollen and tender joint counts, respectively; 54.8% had ≥50% improvement from baseline in American College of Rheumatology response criteria (ACR50). Among patients with baseline enthesitis (n = 355) or dactylitis (n = 137), complete resolution occurred in 56.6% and 68.6%, respectively. Among patients with baseline psoriasis affecting ≥3% of body surface area (BSA; n = 621), 64.6% attained 100% improvement in Psoriasis Area and Severity Index (PASI100); in those with baseline nail psoriasis (n = 642), 68.0% attained modified Nail Psoriasis Severity Index (mNAPSI) = 0. Inflammatory bowel disease (IBD) and uveitis events were reported in 6 and 4 patients, respectively. High-sensitivity C-reactive protein (hs-CRP) normalization rates were 69.4% at Year 1 and 63.2% at Year 3; mean neutrophil-to-lymphocyte ratio (NLR) values were 2.2 and 2.3, respectively.

Key learning: In this post hoc analysis, bimekizumab demonstrated sustained disease control across GRAPPA domains assessed through 3 years in patients with PsA, alongside few reported IBD and uveitis events and sustained improvements in systemic inflammation markers. These findings provide further evidence of the potential for long-term disease control with bimekizumab across the heterogeneous manifestations of PsA.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.